United Therapeutics (UTHR) CEO sells shares under preset trading plan
Martine Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), through a family trust, exercised 9,500 stock options at $135.42 per share and then sold the corresponding 9,500 common shares in multiple open-market trades at weighted average prices around the low-$500s per share on August 18, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After these transactions, the family trust holds 113,410 stock options, and Rothblatt directly holds 40,513 shares, with an additional 166 shares held indirectly by her spouse.
ETFs Investing in United Therapeutics Corporation Stocks
This article lists Exchange Traded Funds (ETFs) that hold stocks of United Therapeutics Corporation (UTHR), providing detailed information for each fund such as market value, weight of UTHR stock, issuer, management style, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV total return. The ETFs cover various market capitalizations and investment styles, offering investors options to access UTHR stock.
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised 9,500 stock options and subsequently sold 9,500 common shares on August 14, 2026, generating approximately $3.45 million in pre-tax spread. These transactions were executed under a pre-arranged 10b5-1 trading plan. Following the trades, Rothblatt's family trusts retain 132,410 stock options, along with various direct and indirect holdings of common stock.
United Therapeutics CEO Martine Rothblatt sells $4.79m in stock
Martine A. Rothblatt, CEO of United Therapeutics Corp (NASDAQ:UTHR), sold approximately $4.79 million worth of common stock on August 13, 2026, following the exercise of stock options. The transactions were conducted under a pre-arranged 10b5-1 trading plan. The article also mentions United Therapeutics' recent Q2 2026 earnings, which showed an EPS beat but a revenue shortfall, leading to a lowered price target from BofA Securities.
United Therapeutics (UTHR) CEO Rothblatt exercises 9,500 options and sells 9,500 shares via 10b5-1 plan
United Therapeutics Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at $135.42 per share and subsequently sold 9,500 common shares for weighted-average prices between $500 and $513 per share. These transactions were conducted on August 13, 2026, under a pre-arranged Rule 10b5-1 trading plan established on November 7, 2025. After these transactions, the family trust retains 141,910 stock options, and Rothblatt holds additional shares directly and indirectly.
United Therapeutics CEO Rothblatt sells $4.89m in stock
Martine A. Rothblatt, CEO of United Therapeutics Corp, sold approximately $4.89 million worth of company stock on August 12, 2026, as part of a pre-arranged trading plan, while also exercising options to acquire shares. These sales occurred after UTHR stock saw a 60% return over the past year, though it is considered overvalued. Additionally, the company recently reported mixed Q2 2026 earnings, with an EPS beat but a revenue miss, leading BofA Securities to lower its price target.
United Therapeutics Corp (UTHR) CEO’s trust sells 9,500 shares under 10b5-1 plan
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), had a family trust execute and sell 9,500 shares. This transaction, conducted on August 12, 2026, was part of a pre-arranged Rule 10b5-1 trading plan. The trust exercised 9,500 stock options at $135.42 and then sold the common shares at weighted-average prices between $507 and $521 per share.
United Therapeutics Corp (UTHR) CEO trades 9,500 shares after option exercise
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, through a family trust, exercised 9,500 stock options at $135.42 per share and subsequently sold 9,500 common shares between $512.94 and $531.29 per share on August 11, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following these trades, the family trust's holdings included 160,910 stock options and various direct and indirect common stock shares.
UNITED THERAPEUTICS CORP (UTHR.MX) Analyst insights, Price targets and Recommendations
This article provides analyst insights, price targets, and recommendations for UNITED THERAPEUTICS CORP (UTHR.MX). It lists recent upgrades and downgrades from various financial institutions like RBC Capital, JP Morgan, B of A Securities, and Wells Fargo, detailing their maintained or changed ratings. The stock last closed at 9,680.00 MXN.
United Therapeutics (UTHR) CEO trades 9,500 shares under 10b5-1 plan
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), exercised 9,500 stock options at $135.42 per share and subsequently sold these 9,500 common shares in open-market transactions ranging from $523 to $539 per share on August 10, 2026. This activity was conducted under a pre-arranged Rule 10b5-1 trading plan established on November 7, 2025. Following these transactions, family trusts associated with Rothblatt still hold 170,410 stock options expiring in March 2027.
United Therapeutics chairperson & CEO sells $5.05m in stock
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp. (NASDAQ:UTHR), sold 9,500 shares of company stock worth over $5 million on August 7, 2026, after exercising stock options. These transactions were executed under a pre-arranged 10b5-1 trading plan. The article also mentions United Therapeutics' mixed Q2 2026 financial results and a revised price target from BofA Securities.
Baylor College of Medicine strikes multimillion-dollar deal with United Therapeutics for transplant center
Baylor College of Medicine and United Therapeutics have signed a multimillion-dollar agreement to establish the Baylor College of Medicine Center for Xenoliver Transplantation and Immunomodulation. This partnership coincides with United Therapeutics' upcoming opening of its nearly $100 million xenotransplantation facility in Houston. The collaboration aims to advance transplant medicine.
Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock
Martine Rothblatt, CEO of United Therapeutics (NASDAQ:UTHR), sold 9,500 shares of the company's stock for over $5 million, reducing her stake by 2.84%. The sale occurred on August 7th at an average price of $531.38 per share. Despite the sale, United Therapeutics beat earnings expectations with an EPS of $7.27, though revenue missed estimates, and the company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $646.
United Therapeutics (UTHR) CEO trades 9,500 shares under 10b5-1 option plan
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), exercised 9,500 stock options at $135.42 per share and simultaneously sold 9,500 common shares for approximately $525-$540 per share on August 7, 2026. These transactions were executed through a family trust under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following these trades, the trust holds 179,910 stock options and Rothblatt maintains direct and indirect common stock holdings.
United Therapeutics (UTHR) CEO sells 9,500 shares after option exercise
United Therapeutics Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares at $135.42 and subsequently sold these shares through a family trust in multiple transactions ranging from $512.50 to $532.3932 per share. These transactions, executed on August 6, 2026, were part of a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. After these transactions, the family trust still holds 189,410 options, in addition to other direct and indirect share holdings.
United Therapeutics Corp (UTHR) CEO sells 9,500 shares under 10b5-1 plan
United Therapeutics Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at $135.42 per share and subsequently sold 9,500 shares in multiple transactions on August 5, 2026. These actions were conducted under a pre-arranged 10b5-1 trading plan established on November 7, 2025. Following these trades, Rothblatt's family trust retains 198,910 stock options, and she directly holds 40,513 common shares, alongside other indirect holdings.
Earnings Flash (UTHR) United Therapeutics Corporation Reports Q2 Revenue $783.3M, vs. FactSet Est of $804.6M
United Therapeutics Corporation (UTHR) reported its Q2 revenue at $783.3 million, falling short of FactSet's estimate of $804.6 million. This earnings flash highlights the pharmaceutical company's financial performance for the second quarter, providing key revenue figures against analyst expectations.
Earnings call transcript: United Therapeutics posts Q2 2026 EPS beat, revenue miss
United Therapeutics reported mixed Q2 2026 results, beating EPS estimates with $7.27 per share but missing revenue forecasts at $783.3 million. The stock fell in premarket trading as investors focused on the sales miss and cautious near-term outlook despite pipeline progress in IPF, PAH, and xenotransplantation. Management expects a stronger second half of 2026 due to an expanded sales force but did not update full-year revenue guidance.
United Therapeutics (UTHR) CEO trades 9,500 shares under 10b5-1 plan
United Therapeutics (UTHR) CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.42 per share and subsequently sold these shares in multiple tranches at weighted average prices between $512.4859 and $517.4960 on August 4, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. After these trades, Rothblatt retains significant holdings, including additional stock options and common shares held directly and indirectly.
United Therapeutics (UTHR) lifts Q2 EPS, details $2.0B share buyback plan
United Therapeutics reported Q2 2026 financial results, with net income rising to $333.0 million and diluted EPS to $7.27, despite a 2% decrease in total revenues to $783.3 million. The company announced a $2.0 billion share repurchase program, including $1.5 billion in accelerated repurchases, and highlighted significant progress in its pipeline with NDA submissions for ralinepag tablets and Nebulized Tyvaso, as well as plans for new xeno-organ production facilities.
BofA cuts United Therapeutics stock price target on Tyvaso sales
BofA Securities lowered its price target for United Therapeutics Corp. (NASDAQ:UTHR) to $559 from $613, while maintaining a Neutral rating, due to weaker-than-expected Tyvaso sales and competitive pressures. The company's second-quarter results included a revenue miss, leading BofA to reduce its fiscal 2026 sales estimates for Tyvaso. Despite plans to double its sales force, the firm now projects flat year-over-year Tyvaso growth for 2026, lowering previous expectations for double-digit growth.
Press Release: United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
United Therapeutics Corporation announced its financial results for the second quarter of 2026. The report details the company's financial performance, likely including revenue, net income, and earnings per share, for the specified period. This press release provides key insights into the company's operational and financial health.
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares after option exercise
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (NASDAQ: UTHR), exercised 9,500 stock options and subsequently sold 9,500 shares of common stock on August 3, 2026. These transactions, executed through family trusts under a pre-arranged 10b5-1 trading plan, involved an exercise price of $135.42 per share and sale prices ranging between $514.83 and $518.61 per share. After these trades, Rothblatt's family trust still holds 217,910 options, and she directly holds 40,513 shares, along with 166 shares indirectly via a spouse.
United Therapeutics earnings on deck after first-quarter miss By Investing.com
United Therapeutics is scheduled to report its second-quarter earnings, with analysts anticipating an improvement from a disappointing first quarter. Investors will be closely watching the performance of its pulmonary arterial hypertension (PAH) franchise and updates on the company's diversification strategy. Despite recent stumbles, Wall Street analysts largely maintain optimistic ratings for the stock.
United Therapeutics Corp (UTHR) CEO sells 9,500 shares under plan
United Therapeutics Corp's Chairperson & CEO, Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.42 per share on July 31, 2026. On the same day, the trusts sold these 9,500 shares in multiple transactions at weighted-average prices, all under a pre-arranged 10b5-1 trading plan. After these transactions, Rothblatt's family trust still holds 227,410 options, while she also holds 40,513 shares directly and 166 shares indirectly through her spouse, plus other trust holdings.
Precision Trading with United Therapeutics Corporation (UTHR) Risk Zones
This article provides a precision trading analysis for United Therapeutics Corporation (UTHR), indicating divergent sentiment across various time horizons and suggesting choppy conditions. It highlights a breakdown in progress with elevated downside risk and offers three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis. The report also mentions AI-generated signals for support and resistance levels.
Form 4 United Therapeutics Corporation For: 31 July By Investing.com
This article provides details of a Form 4 filing for United Therapeutics Corporation (UTHR) related to activity on July 31. It appears to be a standard notification of insider transactions or changes in ownership. The article itself is very brief, serving primarily as an announcement of the filing.
United Therapeutics CEO Rothblatt sells $4.9m in shares By Investing.com
Martine A. Rothblatt, CEO of United Therapeutics Corp, recently sold approximately $4.99 million worth of shares after exercising stock options under a pre-arranged 10b5-1 trading plan. The sale of 9,500 shares occurred on July 30, 2026, following the exercise of options at a lower price. This transaction comes after a significant 91% surge in UTHR shares over the past year.
United Therapeutics (UTHR) CEO trusts exercise options, sell 9,500 shares
United Therapeutics CEO Martine A. Rothblatt, through family trusts, exercised options for 9,500 shares at a strike price of $135.42 and subsequently sold all 9,500 shares in the low $520s. This transaction, executed under a pre-arranged Rule 10b5-1 trading plan, resulted in an approximate pre-tax spread of $3.70 million. The trading plan, adopted on November 7, 2025, covers 1,734,410 stock options expiring by March 15, 2027, or December 31, 2026.
United Therapeutics CEO Martine Rothblatt sells $4.96 million in stock
Martine A. Rothblatt, CEO of United Therapeutics Corp, sold 9,500 shares of company stock for approximately $4.96 million after exercising stock options. The transactions were conducted under a pre-arranged 10b5-1 trading plan. Despite the sale, Rothblatt continues to indirectly hold a significant number of shares and options through family trusts.
United Therapeutics CEO Martine Rothblatt sells $4.96 million in stock
Martine A. Rothblatt, CEO of United Therapeutics Corp, sold 9,500 shares worth $4.96 million on July 29, 2026, after exercising stock options. The sale was executed under a pre-arranged 10b5-1 trading plan and occurred after an 86% return in the stock over the past year. Rothblatt continues to hold a significant number of shares and stock options indirectly through family trusts.
United Therapeutics (UTHR) CEO exercises 9,500 options, sells shares under plan
United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.42 per share and subsequently sold these 9,500 shares on July 29, 2026, under a pre-arranged 10b5-1 trading plan. The shares were sold in multiple open-market transactions with weighted-average prices ranging from approximately $518.25 to $525.46. After these transactions, Rothblatt's family trusts still hold a significant number of stock options and common stock, in addition to direct and indirect holdings.
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
United Therapeutics announced that the ADVANCE OUTCOMES study of ralinepag for pulmonary arterial hypertension (PAH) has been published in The Lancet. The study, which included predominantly pre-treated patients, met its primary endpoint by reducing the risk of a clinical worsening event by 55% compared to placebo. Ralinepag demonstrated durable efficacy, improved key secondary endpoints like NT-proBNP and six-minute walk distance, and showed a safety profile consistent with known prostacyclin pathway effects.
United Therapeutics Corp (UTHR) CEO trades 9,500 shares in option exercise
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options and subsequently sold 9,500 common shares on July 28, 2026. These transactions were executed under a pre-arranged 10b5-1 trading plan adopted in November 2025. Following the sales, Rothblatt maintains significant direct and indirect holdings in the company, including 255,910 remaining options in a family trust.
United Therapeutics CEO Rothblatt sells $5 million in shares
Martine A. Rothblatt, CEO of United Therapeutics Corp, sold 9,500 shares for approximately $5 million on July 28, 2026, after exercising stock options. This transaction was part of a pre-arranged 10b5-1 trading plan adopted in November 2025. Despite the insider sale, the company has seen aggressive share buybacks and recent positive developments, including FDA approval for a lung perfusion device and reiterated Buy ratings from analysts.
Form 4 United Therapeutics Corporation For: 28 July By Investing.com
The article reports on a Form 4 filing for United Therapeutics Corporation (UTHR) which was made on July 28. It provides minimal details about the filing itself, primarily serving as an announcement of the document's existence rather than offering insights into its content. The article is very concise and includes standard market data and navigation elements from the Investing.com platform.
United Therapeutics Number of Employees 2026 | Employee Count & Headcount Data
United Therapeutics Corp. (UTHR) had approximately 1,461 total employees worldwide as of March 2026, representing a 26.4% growth from 2023. The company is actively hiring with 158 active job postings in 2026, and its workforce is primarily concentrated in North America. Employee sentiment is noted as negative and declining.
Price to book ratio of United Therapeutics Corporation – HAM:UTH
This page from TradingView displays financial information, specifically the price-to-book ratio, for United Therapeutics Corporation (UTH) on the Hamburg Stock Exchange. The market appears to be closed with no trades showing. The article provides a chart or table for the period, value, and change of the price-to-book ratio.
United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares
United Therapeutics Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at $135.42 and simultaneously sold the resulting 9,500 common shares for approximately $5.04 million under a pre-arranged 10b5-1 trading plan. The sales occurred on July 27, 2026, at prices ranging from $526 to $535 per share through family trusts. Following these transactions, a trust retains 265,410 options, and Rothblatt holds 40,513 shares directly, among other indirect holdings.
United Therapeutics CEO Rothblatt sells $5 million in shares
Martine A. Rothblatt, CEO of United Therapeutics Corp, sold approximately $5 million worth of common stock on July 27, 2026, alongside exercising stock options. These transactions were executed under a pre-arranged 10b5-1 trading plan. Despite the sales, Rothblatt maintains significant indirect holdings in the company.
United Therapeutics (UTHR) CEO sells 9,500 shares after option exercise
United Therapeutics Chairperson & CEO Martine A. Rothblatt reported that family trusts with which she shares investment power exercised 9,500 stock options and sold 9,500 shares of common stock on July 24, 2026. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, the trusts continue to hold 274,910 stock options and Rothblatt directly owns 40,513 common shares.
United Therapeutics CEO Rothblatt sells $5.05 million in stock
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (NASDAQ:UTHR), sold approximately $5.05 million worth of common stock on July 24, 2026, through a pre-arranged 10b5-1 trading plan. The sale followed the exercise of stock options and occurred after the stock's significant 73.55% return over the past year. Rothblatt continues to hold a substantial number of shares directly and indirectly through various trusts.
People on the Move: Victor Dzau, M.D., Joins United Therapeutics as Board Member
United Therapeutics Corporation has appointed Victor Dzau, M.D., to its Board of Directors, effective July 22, 2026, as part of its ongoing board refreshment efforts. Dr. Dzau brings extensive experience as a physician-scientist and global health leader, having previously served as President of the National Academy of Medicine and holding significant roles at Duke University and Harvard Medical School. His appointment is expected to support United Therapeutics' mission to develop therapies for rare diseases and pioneering alternatives for transplantable organs.
United Therapeutics Corp (NASDAQ: UTHR) CEO trades 9,500 shares in 10b5-1 plan
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised 9,500 stock options and subsequently sold the resulting 9,500 shares through family trusts on July 23, 2026. The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. After these trades, Rothblatt retains significant holdings directly and indirectly through various family trusts.
United Therapeutics (UTHR) awards director 760 restricted stock units
United Therapeutics Corporation (UTHR) director Kevin Tracey was awarded 760 restricted stock units (RSUs) on July 22, 2026, as part of an annual non-employee director equity award. These RSUs convert to one share of common stock each upon vesting, which is anticipated to occur fully by June 25, 2027, the next Annual Meeting of Shareholders. Following this grant, Tracey directly holds 760 RSUs.
Liquidia vs. United Therapeutics: Which PAH Stock Is the Better Buy Now?
This article analyzes Liquidia (LQDA) and United Therapeutics (UTHR) to determine which is the better investment in the pulmonary arterial hypertension (PAH) market. While United Therapeutics is an established leader with a diverse portfolio, Liquidia presents a stronger growth story driven by the successful launch of its drug Yutrepia, leading to a "Strong Buy" rating for LQDA compared to UTHR's "Buy" rating. The article suggests Liquidia offers greater upside potential for investors seeking higher returns.
United Therapeutics (UTHR) awards RSUs and stock options to director Nilda Mesa
United Therapeutics (UTHR) director Nilda Mesa received annual non-employee director equity awards on July 22, 2026. These awards include 380 restricted stock units and 1,190 stock options, which are expected to vest on the earlier of one year from the grant date or the next Annual Meeting of Shareholders, anticipated for June 25, 2027. Following these awards, Mesa directly holds 5,678 shares of United Therapeutics common stock, and the stock options have an exercise price of $527.0700 and will expire on July 22, 2033.
United Therapeutics (UTHR) grants director 2,380 stock options at $527.07
United Therapeutics Corp director Louis W. Sullivan was granted 2,380 stock options at an exercise price of $527.07 per share as part of an annual non-employee director award. These options vest on the earlier of one year from the grant date or the next Annual Meeting of Shareholders (anticipated June 25, 2027) and expire in July 2033. The filing also corrected a prior clerical error, updating his indirect holdings.
United Therapeutics (UTHR) awards 760 RSUs to board director Judy D. Olian
United Therapeutics (UTHR) director Judy D. Olian was awarded 760 restricted stock units (RSUs) as an annual non-employee director equity award on July 22, 2026. These RSUs will fully vest on the earlier of one year from the grant date or the next Annual Meeting of Shareholders, anticipated on June 25, 2027. Following this transaction, Olian directly holds 760 RSUs and 5,555 shares of common stock.
United Therapeutics (UTHR) awards 2,380 stock options to board director
United Therapeutics (UTHR) awarded 2,380 stock options to board director Christopher Patusky on July 22, 2026. These options have an exercise price of $527.07 per share and expire on July 22, 2033. The award is part of the annual non-employee director compensation and vests on the earlier of one year from the grant date or the next Annual Meeting of Shareholders, anticipated to be June 25, 2027.
